Standard Market Design

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
星期日, 十一月 19, 2023
Temozolomide, Safety, Glioblastoma, Dana–Farber Cancer Institute, GBM, Molecular medicine, Medicine, TMZ, Patient, Tokyo Stock Exchange, Immunohistochemistry, Neoplasm, Integrin alpha M, Harvard Medical School, Survival, CD74, Cleveland Clinic, Society, SNO, CD3, Standard Market Design, Life, Biopsy, Code, Pharmaceutical industry, Neurology

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”

Nidec Announces Notice Regarding the Completion of Purchase and Settlement of Tendered Shares Certificates, etc. in Tender Offer of Takisawa Machine Tool Co., Ltd. (Securities Code: 6121) and its Entry to Nidec Group

Retrieved on: 
星期一, 十一月 20, 2023
Machine Tools, Metalworking & Metallurgy, Robotics, Technology, Manufacturing, Machinery, Hardware, Tender offer, Financial instrument, Tokyo Stock Exchange, Williams Act, Inc., Result, Standard Market Design, Target, Nidec

tendered for the Tender Offer (the “Tendered Share Certificates, etc.”) exceeded the minimum number to be purchased in the Tender Offer, and therefore Nidec Corporation was scheduled to purchase, etc.

Key Points: 
  • tendered for the Tender Offer (the “Tendered Share Certificates, etc.”) exceeded the minimum number to be purchased in the Tender Offer, and therefore Nidec Corporation was scheduled to purchase, etc.
  • Today, we would like to announce that Nidec Corporation has completed the purchase, etc.
  • of 5,502,183 shares in total through Mita Securities Co., Ltd. and Monex Inc. (subagent).
  • As a result, we own 86.14% of the voting rights in the Target Company and it has become a member of Nidec Group.

Nidec Announces the Results of the Tender Offer for Takisawa Machine Tool Co., Ltd. (Securities Code: 6121)

Retrieved on: 
星期二, 十一月 14, 2023
Machine Tools, Metalworking & Metallurgy, Automotive Manufacturing, Technology, Manufacturing, Machinery, Hardware, Financial instrument, Corporation, Nidec, Williams Act, Tokyo Stock Exchange, Standard Market Design, Tender offer, Tender

Nidec Corporation (the “Tender Offeror”) decided on September 13, 2023 to acquire, through a tender offer in accordance with the Financial Instruments and Exchange Act (Act No.

Key Points: 
  • Nidec Corporation (the “Tender Offeror”) decided on September 13, 2023 to acquire, through a tender offer in accordance with the Financial Instruments and Exchange Act (Act No.
  • 25 of 1948, as amended, the “Act”) and related laws and regulations (the “Tender Offer”), the common shares (the “Target Company Shares”) issued by Takisawa Machine Tool Co., Ltd. (Securities Code: 6121.
  • The “Target Company”), which are listed on the Standard Market of the Tokyo Stock Exchange, Inc. (the “Tokyo Stock Exchange”), and launched the Tender Offer on September 14, 2023.
  • The Tender Offeror today announced that the Tender Offer had ended on November 13, 2023.

Nidec Announces Changes to the Press Release, “Notice Regarding Commencement of Tender Offer for Takisawa Machine Tool Co., Ltd. (Securities Code: 6121)” due to Changes in Conditions to the Tender Offer to the Company

Retrieved on: 
星期五, 十月 27, 2023
Machine Tools, Metalworking & Metallurgy, Robotics, Technology, Manufacturing, Machinery, Hardware, Standard Market Design, Graduation, Tender offer, Tender, Tokyo Stock Exchange, Target, OTC, Williams Act, International Ship and Port Facility Security Code, Notice, Paragraph, Financial Instruments and Exchange Act, Corporation, September 21 (Eastern Orthodox liturgics), Public, Nidec, Financial instrument, Press release, Cryptocurrency

25 of 1948, as amended, the “Act”) and related laws and regulations (the “Tender Offer”), the common shares (the “Target Company Shares”) of Takisawa Machine Tool Co., Ltd. (Securities Code: 6121.

Key Points: 
  • 25 of 1948, as amended, the “Act”) and related laws and regulations (the “Tender Offer”), the common shares (the “Target Company Shares”) of Takisawa Machine Tool Co., Ltd. (Securities Code: 6121.
  • The “Target Company”), which is listed on the Standard Market of the Tokyo Stock Exchange, Inc. (the “Tokyo Stock Exchange”), and launched the Tender Offer on September 14, 2023.
  • Accordingly, as explained in the Public Notice of Commencement of the Tender Offer submitted on September 14, 2023 (including the matters amended based on the amendment to the tender offer registration statement for the Tender Offer submitted on September 21 and October 10, 2023: the same shall apply hereinafter), the Tender Offeror, for the purpose of securing a tender offer period of 10 business days from today, decided to extend the period for the Tender Offeror to acquire the Target Company’s common shares in the Tender Offer (the “Tender Offer Period”) until November 13, 2023.
  • Thus, the Tender Offeror amends part of the September 21, 2023 press release, “Notice Regarding Commencement of Tender Offer for Takisawa Machine Tool Co., Ltd. (Securities Code: 6121)” (including the October 10, 2023 press release, “Notice Regarding Changes to the Press Release, “Notice Regarding Commencement of Tender Offer for Takisawa Machine Tool Co., Ltd. (Securities Code: 6121)” due to Submission of Amended Statement of Public Notice of Commencement of the Tender Offer, and Changes to the Notice Regarding Commencement of the Tender Offer”: the same shall apply hereinafter).

MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Retrieved on: 
星期五, 十月 27, 2023
PKU, Standard Market Design, AAV, Tokyo Stock Exchange, Phenylketonuria, Genzyme, Clinical trial, Code, Phenylalanine hydroxylase, PAH, Pharmaceutical industry, Sanofi

LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU).

Key Points: 
  • LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU).
  • SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation.

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Retrieved on: 
星期三, 十月 11, 2023
Patent, ALS, Code, MD, Intellectual property, MPH, Disease, Standard Market Design, FDA, Riluzole, Clinical trial, Tokyo Stock Exchange, Canadian Intellectual Property Office, Patient, Pharmaceutical industry, Doctor of Philosophy

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035.
  • The allowed claims cover a wide range of doses and a range of dosing regimens for both MN-166 (ibudilast) and riluzole.
  • Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased to receive notice that this new patent will be granted.
  • The U.S. FDA granted both orphan-drug designation and fast-track designation to MN-166 for the treatment of ALS, and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS."

MediciNova Receives Gene Therapy Milestone Payment

Retrieved on: 
星期四, 十月 5, 2023
Standard Market Design, Tokyo Stock Exchange, Code, AAV, Sales, Fine chemical, Sanofi

LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi.

Key Points: 
  • LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi.
  • The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on: 
星期四, 九月 28, 2023
ASPR, Code, ALI, Human services, United States Department of Health and Human Services, White lung, Development, MCM, Chlorine, Tokyo Stock Exchange, Biomedical Advanced Research and Development Authority, Acute respiratory distress syndrome, Standard Market Design, BARDA, Safety, Pharmaceutical industry

Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.

Key Points: 
  • Two different nonclinical models were used to investigate the potential clinical utility of MN-166 (ibudilast) for the treatment of chlorine-induced lung damage.
  • The primary endpoint was the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • In the pilot design single-dose treatment regimen, the test subjects were treated only once after the Cl2 gas challenge was completed.
  • There is a great unmet medical need for treatments for chlorine gas exposure as there is no drug approved specifically for this indication.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
星期五, 八月 18, 2023
Co-leaders of the Scottish Green Party, Cleveland Clinic, Code, Case Comprehensive Cancer Center, Clinical trial, SNO, Molecular medicine, Tokyo Stock Exchange, Case Western Reserve University School of Medicine, Poster, Standard Market Design, Pharmaceutical industry, Tobacco, Glioblastoma

LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.

Key Points: 
  • LA JOLLA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.
  • The poster will be presented by MediciNova’s collaborator, Dr. Justin Lathia, Vice Chair in the Department of Cardiovascular and Metabolic Sciences and Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute at Cleveland Clinic; Professor, Department of Molecular Medicine at Case Western Reserve University School of Medicine; and Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center.
  • The presentation details are as follows:

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Retrieved on: 
星期四, 八月 17, 2023
Optical coherence tomography, Patent, Code, Multiple sclerosis, Tablet, Capsule, MD, Tokyo Stock Exchange, OCT, Standard Market Design, MPH, SPRINT, Pharmaceutical industry, Doctor of Philosophy

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.
  • The allowed claims cover a wide range of doses of MN-166 (ibudilast) and a range of different dosing frequencies.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.
  • We are very pleased to receive notice of this new patent which covers Europe, and we believe it could increase the potential value of MN-166.”